Tacrolimus
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Tacrolimus: From Atopic Dermatitis to Seborrheic Dermatitis
One-Sentence Summary
Tacrolimus is a calcineurin inhibitor best known for preventing organ transplant rejection and, in its topical ointment form (Protopic®), for treating atopic dermatitis. The TxGNN model predicts it may also be effective for Seborrheic Dermatitis, with 2 clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atopic dermatitis (topical, Protopic®) / organ transplant rejection prophylaxis (systemic) — based on established drug classification; a specific licensed indication text was not available in this Evidence Pack |
| Predicted New Indication | Seborrheic Dermatitis |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L1 |
| EU Market Status | Not Marketed (per this Evidence Pack — see note in EU Market Information) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not populated in the drug record for this pack, but the evidence pack’s own repurposing rationale provides the relevant pharmacology: tacrolimus is a calcineurin inhibitor that blocks IL-2 gene transcription in T cells, thereby suppressing local inflammatory activation. This is the same mechanism underlying tacrolimus ointment’s established, guideline-recognized use in atopic dermatitis.
Seborrheic dermatitis is a chronic inflammatory skin condition in which impaired skin-barrier function and an abnormal immune-inflammatory response (often linked to Malassezia colonization) drive relapsing erythema and scaling — a pathophysiology that overlaps substantially with atopic dermatitis. Because topical tacrolimus already down-regulates the same T-cell-driven inflammatory cascade in the skin, extending its use to seborrheic dermatitis is mechanistically coherent rather than speculative.
This reasoning is reinforced by direct clinical evidence: two completed trials (one Phase 3, one Phase 4) specifically tested tacrolimus ointment as maintenance therapy for severe facial seborrheic dermatitis in adults, and a substantial literature base — including RCTs and cohort studies — supports its use as an off-label, corticosteroid-sparing treatment option in this condition.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02004860 | Phase 3 | Completed | 120 | Evaluated tacrolimus ointment (Protopic®) as maintenance therapy for severe facial seborrheic dermatitis in adults, aiming to reduce relapse frequency, prolong remission, and reduce topical steroid use |
| NCT01591070 | Phase 4 | Completed | 104 | Assessed proactive once- or twice-weekly application of 0.1% tacrolimus ointment to maintain remission and reduce exacerbation incidence in adult facial seborrheic dermatitis |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33010323 | 2021 | RCT | J Am Acad Dermatol | Multicenter, double-blind RCT comparing tacrolimus 0.1% to ciclopiroxolamine 1% for maintenance therapy in severe facial seborrheic dermatitis — the first long-term maintenance trial in this population |
| 24171300 | 2013 | RCT | Annals of Parasitology | Compared efficacy of sertaconazole 2% cream vs. tacrolimus 0.03% cream in 60 seborrheic dermatitis patients |
| 37067129 | 2023 | RCT | Indian J Dermatol Venereol Leprol | Compared oral itraconazole plus topical tacrolimus vs. topical tacrolimus alone for maintenance treatment of seborrheic dermatitis in Vietnam |
| 26512166 | 2015 | Cohort | Annals of Dermatology | Evaluated 0.1% tacrolimus ointment as maintenance therapy for facial seborrheic dermatitis, building on the proactive-therapy model established in atopic dermatitis |
| 27804089 | 2017 | Systematic Review | Am J Clin Dermatol | Systematic review of topical treatments (antifungals, keratolytics, corticosteroids, calcineurin inhibitors) for facial seborrheic dermatitis |
| 19222250 | 2009 | Review | Am J Clin Dermatol | Reviews pathophysiology, safety, and efficacy of topical calcineurin inhibitors (incl. tacrolimus) as a safe alternative to corticosteroids in seborrheic dermatitis |
| 19213227 | 2009 | Review | J Drugs Dermatol | Overview of facial seborrheic dermatitis pathophysiology and therapeutic horizons, including calcineurin inhibitors |
| 12833030 | 2003 | Open-Label Pilot Study | J Am Acad Dermatol | Single-center open-label pilot in 18 patients: 61% achieved complete clearance of seborrheic dermatitis with 0.1% tacrolimus over 28 days |
| 28685715 | 2017 | Observational | Chinese Medical Journal | Investigated Staphylococcus epidermidis colonization and impaired skin barrier in facial seborrheic dermatitis, supporting an inflammatory/barrier-based rationale for anti-inflammatory topical therapy |
| 16094289 | 2005 | Observational | Jpn J Med Mycology | PCR-based analysis of Malassezia species in seborrheic and atopic dermatitis patients, supporting shared pathophysiologic mechanisms between the two conditions |
EU Market Information
No EU marketing authorization records for tacrolimus were captured in this Evidence Pack (total_licenses = 0, market_status = Not Marketed). Tacrolimus is a long-established active substance with multiple products marketed in the EU (e.g., systemic Prograf®/Advagraf® for transplant rejection prophylaxis, and topical Protopic® for atopic dermatitis); the absence of license records here likely reflects a gap in this dataset’s regulatory-data collection rather than an actual absence of EU authorization, and should be verified against the EMA/national registers before use in decision-making.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two completed trials (Phase 3 and Phase 4) directly evaluate tacrolimus ointment for maintenance treatment of severe facial seborrheic dermatitis, supported by a consistent body of RCT, cohort, and pilot-study literature. The mechanism (calcineurin inhibition → suppression of skin T-cell-driven inflammation) is already clinically validated through the drug’s approved atopic dermatitis indication, giving strong biological plausibility.
To proceed, the following is needed:
- Formal mechanism-of-action documentation for the regulatory dossier (currently a data gap, DG002)
- TFDA/EU product label warnings and contraindications (currently a data gap, DG001 — Blocking for safety review)
- Verification of current EU marketing authorization status for tacrolimus products (discrepancy noted above)
- A dedicated safety monitoring plan for chronic topical use in seborrheic dermatitis (e.g., local skin reactions, photosensitivity, long-term malignancy signal monitoring consistent with class labeling)
- Formal drug-drug interaction review, since no DDI data were returned in this pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.